Aptuit and Aegerion sign commercial API supply agreement
Aptuit and Aegerion sign commercial API supply agreement
Stuart Needleman, President and CEOO, Aptuit, announced that Aptuit and Aegerion Pharmaceuticals (AEGR), Cambridge, Massachusetts, have signed a long-term supply agreement for commercial quantities of the active pharmaceutical ingredient lomitapide. Lomitapide is Aegerion's orphan drug that is targeted to the treatment of a rare disease caused by a genetic disorder. The drug received NDA approval in December of 2012 and is expected to be launched commercially in January of 2013. Previously, Aptuit scientists had established the chemistry for lomitapide, developed and validated its analytical methods, delivered solid state form control and crystallization R&D, and supplied registration ba tches of material. Post-launch, Aptuit will continue to supply commercial quantities of lomitapide to Aegerion.